Researchers unveiled small-molecule-controlled CRISPR editing systems in living tissues, publishing in Science Translational Medicine. Led by Dr. Wang Yu at the Shenzhen Institutes of Advanced Technology (Chinese Academy of Sciences), the team developed PRINCE and Little Prince to switch CRISPR activity on with drug inducers and keep it largely inactive when the inducer is absent. The work addresses a central translational challenge for CRISPR therapeutics—controlling when gene editing occurs to reduce off-target risk and improve safety. The systems are designed around dual small-molecule regulation, aiming for tighter temporal control in vivo. If validated across broader models, drug-inducible genome editing could expand the usable therapeutic window for CRISPR approaches in patients by aligning editing kinetics with dosing schedules.